ES2707232T3 - Acido nucleico bicatenario quimérico - Google Patents

Acido nucleico bicatenario quimérico Download PDF

Info

Publication number
ES2707232T3
ES2707232T3 ES12815856T ES12815856T ES2707232T3 ES 2707232 T3 ES2707232 T3 ES 2707232T3 ES 12815856 T ES12815856 T ES 12815856T ES 12815856 T ES12815856 T ES 12815856T ES 2707232 T3 ES2707232 T3 ES 2707232T3
Authority
ES
Spain
Prior art keywords
nucleic acid
nucleotides
strand
dna
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12815856T
Other languages
English (en)
Spanish (es)
Inventor
Takanori Yokota
Kazutaka Nishina
Satoshi Obika
Hidehiro Mizusawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Tokyo Medical and Dental University NUC
Original Assignee
Osaka University NUC
Tokyo Medical and Dental University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Tokyo Medical and Dental University NUC filed Critical Osaka University NUC
Application granted granted Critical
Publication of ES2707232T3 publication Critical patent/ES2707232T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES12815856T 2011-12-16 2012-12-17 Acido nucleico bicatenario quimérico Active ES2707232T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Publications (1)

Publication Number Publication Date
ES2707232T3 true ES2707232T3 (es) 2019-04-03

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12815856T Active ES2707232T3 (es) 2011-12-16 2012-12-17 Acido nucleico bicatenario quimérico

Country Status (9)

Country Link
US (6) US9816089B2 (instruction)
EP (1) EP2791335B1 (instruction)
JP (7) JP6112569B2 (instruction)
CN (2) CN112386605A (instruction)
AU (1) AU2012353330B2 (instruction)
CA (2) CA2859581C (instruction)
ES (1) ES2707232T3 (instruction)
IN (1) IN2014CN04590A (instruction)
WO (1) WO2013089283A1 (instruction)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
EP2791335B1 (en) * 2011-12-16 2018-11-14 National University Corporation Tokyo Medical and Dental University Chimeric double-stranded nucleic acid
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
AU2014222150A1 (en) * 2013-03-01 2015-09-10 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
JP6300212B2 (ja) * 2013-03-21 2018-03-28 国立大学法人 東京医科歯科大学 二重鎖核酸結合剤、当該結合剤−二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法
JP6604544B2 (ja) * 2013-06-16 2019-11-13 国立大学法人 東京医科歯科大学 エクソンスキッピング効果を有する二本鎖アンチセンス核酸
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 十分に安定化された非対称ｓｉｒｎａ
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EP3353306A4 (en) 2015-09-25 2019-06-05 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2017068791A1 (ja) * 2015-10-23 2017-04-27 レナセラピューティクス株式会社 少なくとも１つのバルジ構造を有する核酸複合体
US20180223280A1 (en) * 2015-10-23 2018-08-09 Rena Therapeutics Inc. Nucleic acid complex
WO2017094745A1 (ja) * 2015-12-01 2017-06-08 国立大学法人大阪大学 核酸を含む経腸投与用組成物
BR112018015164A2 (pt) * 2016-01-26 2018-12-26 Nissan Chemical Corp oligonucleotídeo de fita simples
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3517610A4 (en) * 2016-09-23 2020-05-27 National University Corporation Tokyo Medical and Dental University Blood-brain barrier permeable heteroduplex nucleic acid
WO2018062510A1 (ja) 2016-09-29 2018-04-05 国立大学法人東京医科歯科大学 オーバーハングを有する二本鎖核酸複合体
TWI830693B (zh) 2017-02-06 2024-02-01 日商日產化學工業股份有限公司 單股寡核苷酸
WO2018181428A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
JP7141621B2 (ja) * 2017-03-31 2022-09-26 学校法人 愛知医科大学 コンドロイチン硫酸生合成を阻害するアンチセンス核酸
EP3647423A4 (en) * 2017-06-30 2021-03-24 National University Corporation Tokyo Medical and Dental University STRAIGHT DOUBLE-STRANDED ANTI-MIRROR
US11555188B2 (en) 2017-07-26 2023-01-17 Nissan Chemical Corporation Single-stranded oligonucleotide
JP2021506239A (ja) 2017-12-14 2021-02-22 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 複合アンチセンス化合物及びその使用
WO2019167995A1 (ja) 2018-02-28 2019-09-06 国立大学法人東京医科歯科大学 虚血病変部位特異的な遺伝子治療法
KR20190110043A (ko) * 2018-03-19 2019-09-27 주식회사 케이티 비디오 신호 처리 방법 및 장치
JP7333079B2 (ja) 2018-03-19 2023-08-24 国立大学法人 東京医科歯科大学 毒性が軽減した核酸
CN111868244A (zh) 2018-03-20 2020-10-30 国立大学法人东京工业大学 降低了毒性的反义寡核苷酸
WO2019182109A1 (ja) * 2018-03-22 2019-09-26 国立大学法人東京医科歯科大学 ヘテロ核酸のｂｂｂ通過脂質リガンド
JP2022523467A (ja) * 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ 動的な薬物動態を修飾するアンカー
WO2020209285A1 (ja) * 2019-04-08 2020-10-15 国立大学法人東京医科歯科大学 筋疾患治療用医薬組成物
EP4005602A4 (en) 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
WO2021070959A1 (ja) * 2019-10-11 2021-04-15 国立大学法人東京医科歯科大学 修飾ヘテロ核酸
WO2021146548A1 (en) * 2020-01-17 2021-07-22 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
EP4098747A4 (en) 2020-01-31 2025-03-26 Sanwa Kagaku Kenkyusho Co., Ltd. ATN1 ANTISENSE OLIGONUCLEOTIDE
US20230159925A1 (en) 2020-03-04 2023-05-25 Nissan Chemical Corporation Antisense oligonucleotide of calm2
WO2021187392A1 (ja) * 2020-03-16 2021-09-23 国立大学法人東京医科歯科大学 モルホリノ核酸を含むヘテロ核酸
US20230322840A1 (en) 2020-06-15 2023-10-12 Liid Pharmaceuticals, Inc. Bridged nucleoside and nucleotide
CA3202708A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
WO2022183102A1 (en) * 2021-02-26 2022-09-01 Northwestern University Cell-free biosensors with dna strand displacement circuits
EP4349986A1 (en) 2021-05-25 2024-04-10 National University Corporation Tokyo Medical and Dental University Heteronucleic acid containing scpbna or amna
EP4353266A1 (en) 2021-05-31 2024-04-17 Rena Therapeutics Inc. Ligand-bound nucleic acid complex
EP4389891A1 (en) 2021-08-19 2024-06-26 National University Corporation Tokyo Medical and Dental University Modified heteronucleic acid containing morpholino nucleic acid
WO2023026994A1 (ja) 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
WO2023042876A1 (ja) * 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 ２'－修飾ヌクレオシドを含むヘテロ核酸
JPWO2023080159A1 (instruction) 2021-11-02 2023-05-11
CN118660965A (zh) * 2021-12-07 2024-09-17 Liid制药股份有限公司 反义寡核苷酸复合体
JPWO2024071099A1 (instruction) 2022-09-29 2024-04-04
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024228398A1 (ja) * 2023-05-02 2024-11-07 国立大学法人東京医科歯科大学 グアニン四重鎖構造を誘導するための核酸剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
ATE293123T1 (de) 1997-09-12 2005-04-15 Exiqon As Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
WO2003042385A2 (en) * 2001-11-12 2003-05-22 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
AU2003247521A1 (en) * 2002-06-26 2004-01-19 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
WO2004027030A2 (en) * 2002-09-18 2004-04-01 Isis Pharmaceuticals, Inc. Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
EP2336318B1 (en) * 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
NZ576775A (en) * 2003-09-18 2010-12-24 Isis Pharmaceuticals Inc Modulation of eIF4E expression
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2011204898A1 (en) * 2004-04-09 2011-08-11 Biodelivery Sciences International, Inc Nucleotide-cochleate compositions and methods of use
US20080199960A1 (en) * 2004-05-13 2008-08-21 Juliano Rudolph L Methods for the Delivery of Oligomeric Compounds
WO2006074108A2 (en) * 2004-12-30 2006-07-13 Hauser Todd M Compositions and methods for modulating gene expression using self-protected oligonucleotides
ES2471978T3 (es) 2006-05-05 2014-06-27 Isis Pharmaceuticals, Inc. Compuestos y procedimientos para modular la expresión de ApoB
US8673548B2 (en) 2006-08-10 2014-03-18 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
CA2666191C (en) 2006-10-09 2017-07-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
EP2134736A4 (en) * 2007-03-15 2013-05-29 Jyoti Chattopadhyaya FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2133425A1 (en) * 2008-06-13 2009-12-16 Karin Mölling Method and compound for antiviral (HIV) therapy
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
AU2010306940A1 (en) * 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2791335B1 (en) * 2011-12-16 2018-11-14 National University Corporation Tokyo Medical and Dental University Chimeric double-stranded nucleic acid
ES2700277T3 (es) * 2013-05-30 2019-02-14 Univ Nat Corp Tokyo Medical & Dental Agentes de doble cadena para el suministro de oligonucleótidos terapéuticos

Also Published As

Publication number Publication date
JP6638923B2 (ja) 2020-02-05
JP2022171811A (ja) 2022-11-11
JP2015502134A (ja) 2015-01-22
US20190270996A1 (en) 2019-09-05
AU2012353330B2 (en) 2018-04-19
JP6960123B2 (ja) 2021-11-05
JP6112569B2 (ja) 2017-04-12
US9816089B2 (en) 2017-11-14
US20240158790A1 (en) 2024-05-16
US20180073024A1 (en) 2018-03-15
JP2022000426A (ja) 2022-01-04
US11034955B2 (en) 2021-06-15
JP2020039364A (ja) 2020-03-19
CA2859581C (en) 2022-03-22
US10337006B2 (en) 2019-07-02
US10329567B2 (en) 2019-06-25
IN2014CN04590A (instruction) 2015-09-18
US20140302603A1 (en) 2014-10-09
WO2013089283A1 (en) 2013-06-20
US20180320181A1 (en) 2018-11-08
JP2017140031A (ja) 2017-08-17
JP6416301B2 (ja) 2018-10-31
EP2791335B1 (en) 2018-11-14
JP7423015B2 (ja) 2024-01-29
CA3106312A1 (en) 2013-06-20
JP2018203779A (ja) 2018-12-27
US12344841B2 (en) 2025-07-01
CN104126010B (zh) 2021-04-06
CN104126010A (zh) 2014-10-29
CA2859581A1 (en) 2013-06-20
AU2012353330A1 (en) 2014-07-31
JP2021011501A (ja) 2021-02-04
US20210340540A1 (en) 2021-11-04
JP7174384B2 (ja) 2022-11-17
EP2791335A1 (en) 2014-10-22
CN112386605A (zh) 2021-02-23

Similar Documents

Publication Publication Date Title
ES2707232T3 (es) Acido nucleico bicatenario quimérico
ES2700277T3 (es) Agentes de doble cadena para el suministro de oligonucleótidos terapéuticos
JP6440170B2 (ja) キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
CN113166759B (zh) 经化学修饰的RNAi构建体及其用途
EA035756B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
CN114761557A (zh) 具有最小氟含量的小干扰rna的化学修饰
JP2024527584A (ja) ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
CN119013402A (zh) 调节scap活性的组合物和方法
WO2020262555A1 (ja) 核酸医薬副作用軽減剤、該核酸医薬副作用軽減剤を含む医薬組成物、並びに核酸医薬の副作用惹起性を軽減する方法